NICE has announced that the Highly specialised technologies evaluation committee (HSTEC) have made an initial decision not to approve tofersen for use in the NHS in England.
While this is a disappointing outcome for the MND community, their decision is pending further evidence from Biogen, with an expected final outcome in March 2027. We are also extremely disappointed with this initial outcome, however, we understand that it is common for drugs appraised by NICE’s HSTEC to require further evidence and appraisal after the initial outcome, before a final decision is reached.
On 22 October 2026, the committee met to appraise the use of tofersen for treating amyotrophic lateral sclerosis (ALS) caused by SOD1 gene changes in England. MND Scotland attended this online meeting where the committee heard evidence from the manufacturer, Biogen, clinicians, and people living with SOD1 MND who are currently receiving tofersen. In October Biogen submitted tofersen for evaluation by the Scottish Medicines Consortium (SMC), who appraise drugs for use in the NHS in Scotland. MND Scotland is working with both Biogen and SMC to help ensure that the evaluation of tofersen is undertaken with a full picture of the impact of this treatment. At the start of December, we will be sending out a survey to people affected by MND as part of this preparation.
Tofersen is a drug, produced by Biogen, that binds to the part of the SOD-1 gene that carries the instructions for making the SOD-1 protein. About 2-3% of people with MND have a change in their SOD-1 gene that is associated with developing MND. This gene change results in the production of a SOD-1 protein that misfolds and clumps together in motor neurons, causing damage. Tofersen acts upon the SOD-1 gene to reduce the amount of SOD-1 protein produced, which has been shown to slow progression, and in some cases, improve the symptoms, of MND.
We support the MND Association’s call for Biogen and NICE to work together to find a way to make Tofersen available for people with MND who need it.
While the NICE and SMC considerations are progressing, Biogen continues to operate an Early Access Programme (EAP) in the UK for tofersen. This is being offered at specific sites around the UK, although there are no sites currently in Scotland. NICE have confirmed that people already receiving tofersen via the EAP will not see a change in their treatment as a result of this initial recommendation.. Anyone with MND in the UK who has the SOD1 gene change, and would like to be considered for the EAP, should contact their neurologist for more information on whether they might be eligible for referral to an EAP centre in England or Wales.
Further information
- Our article from December 2025: NICE assessment of tofersen to begin in 2026 – MND Scotland
- Our article from July 2025: https://mndscotland.org.uk/news/tofersen-receives-mhra-approval/
- Biogen Early Access Programmes webpage – Early Access Programs | Biogen
- NICE tofersen consultation recommendations – 1 Recommendations | Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations | Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767] | Consultations | NICE